A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

Description

This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).

Conditions

Lupus Nephritis

Talk to us

Study Overview

On this page

Study Details

Study overview

This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

Condition
Lupus Nephritis
Intervention / Treatment

-

Contacts and Locations

S. Gate

Site 00-05, S. Gate, California, United States, 90280

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Lupus nephritis (LN) confirmed by biopsy
  • * Initiating or have initiated treatment with commercial LUPKYNIS as per US approved Prescribing Information (PI)
  • * Written informed consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Aurinia Pharmaceuticals Inc.,

Aurinia Study Director, STUDY_DIRECTOR, Aurinia Pharmaceuticals Inc.

Study Record Dates

2030-06-01